CoChat

Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival

Open access
Casal-Mouriño, Ana, Ruano-Ravina, Alberto, Lorenzo-González, María, Rodríguez-Martínez, Ángeles, Giraldo-Osorio, Alexandra, Varela-Lema, Leonor, Pereiro-Brea, Tara, Barros-Dios, Juan Miguel, Valdés-Cuadrado, Luis, Pérez-Ríos, Mónica · 2021 · Translational Lung Cancer Research
Cited by 177

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Stage III non-small cell lung cancer (NSCLC) includes a highly heterogeneous group of patients with differences in the extent and localization of disease. Many aspects of stage III disease are controversial. The data supporting treatment approaches are often subject to a number of limitations, due to the heterogeneous patient populations involved in the trials. Furthermore, the definition of stage III disease has changed over time, and early studies were frequently inadequately powered to detect small differences in therapeutic outcome, were not randomized, or had a limited follow-up times. Major improvements in therapy, including the use of more active chemotherapy agents and refinements in radiation and surgical techniques, also limit the interpretation of earlier clinical trials. Lastly, improvements in pretreatment staging have led to reclassification of patients with relatively minimal metastatic disease as stage IV rather than stage III, leading to an apparent increase in the overall survival of both stage III and IV patients. Median overall stage III NSCLC survival ranges from 9 to 34 months. Higher survival rates are observed in younger Caucasian women with good performance status, adenocarcinoma, mutations, stage IIIA, and in patients with multidisciplinary-team-based diagnoses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21037/tlcr.2020.03.40

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Metadata

Authors
Casal-Mouriño, A., Ruano-Ravina, A., Lorenzo-González, M., Rodríguez-Martínez, Á., Giraldo-Osorio, A., Varela-Lema, L., Pereiro-Brea, T., Barros-Dios, J. M., Valdés-Cuadrado, L., & Pérez-Ríos, M.
Venue
Translational Lung Cancer Research
Published
2021-01
Volume
10
Issue
1
Pages
506-518
ISSN
  • 2218-6751 (ISSN-L)
  • 2226-4477
OpenAlex
W3022263550
Cited by
177
References
3
FWCI
13.62
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. https://app.cochat.ai/papers/10.21037/tlcr.2020.03.40
The paper
Casal-Mouriño, A., Ruano-Ravina, A., Lorenzo-González, M., Rodríguez-Martínez, Á., Giraldo-Osorio, A., Varela-Lema, L., Pereiro-Brea, T., Barros-Dios, J. M., Valdés-Cuadrado, L., & Pérez-Ríos, M. (2021). Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Translational Lung Cancer Research. https://doi.org/10.21037/tlcr.2020.03.40

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.